Jiangsu Hengrui Medicine
600276.SS
#494
Rank
$40.43 B
Marketcap
$6.34
Share price
-0.62%
Change (1 day)
1.59%
Change (1 year)
Jiangsu Hengrui Medicine Company Limited is a Chinese pharmaceutical company engaged in the R&D, manufacturing and sales of healthcare products, including antineoplastic drugs, angiomyocardiac drugs, drugs for surgery, contrast agents and antibiotics

Earnings for Jiangsu Hengrui Medicine (600276.SS)

Earnings in 2024 (TTM): $0.82 Billion USD

According to Jiangsu Hengrui Medicine 's latest financial reports the company's current earnings are $3.63 Billion USD. In 2023 the company made an earning of $0.65 Billion USD, an increase over its 2022 earnings that were of $0.59 Billion USD. The earnings displayed on this page is the company's Pretax Income.

Earnings history for Jiangsu Hengrui Medicine from 2002 to 2024

Annual earnings

Year Earnings Change
2024 (TTM) $0.82 B25.74%
2023 $0.65 B11.4%
2022 $0.59 B-13.65%
2021 $0.68 B-34.21%
2020 $1.04 B15.95%
2019 $0.89 B33.03%
2018 $0.67 B20.89%
2017 $0.55 B23.89%
2016 $0.45 B11.21%
2015 $0.40 B39.5%
2014 $0.29 B20.61%
2013 $0.24 B11.46%
2012 $0.21 B29.7%
2011 $0.16 B31.16%
2010 $0.12 B27.92%
2009 $99.45 M5.8%
2008 $93.99 M79.95%
2007 $52.23 M32.89%
2006 $39.3 M38.19%
2005 $28.44 M21.56%
2004 $23.4 M13.95%
2003 $20.53 M38.06%
2002 $14.87 M